VCA-894A

Small molecule

VVanda Pharmaceuticals

VCA-894A is one of 9 small molecule programs targeting Charcot-Marie-Tooth disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Charcot-Marie-Tooth DiseaseActive, not recruiting

Charcot-Marie-Tooth DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Charcot-Marie-Tooth Disease

#DrugCompanyPhaseTrials

Lioresal

Mexitil

Coenzyme Q10

1 4

Engensis

HHelixmith Co., Ltd.

Phase 2

1 5

ACE-083

Merck & Co.

Phase 2

1 6

NMD670

NNMD Pharma A/S

Phase 2

1 7

FLX-787-ODT

FFlex Pharma, Inc.

Phase 2

1 8

EN001

EENCell

Phase 1

1 9

VCA-894A

VVanda Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Charcot-Marie-Tooth disease1 trial

Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient

Active, not recruiting·VVanda Pharmaceuticals·Phase 1/2·NCT07223632·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VCA-894A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VCA-894A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VCA-894A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanda Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: VVanda Pharmaceuticals

VCA-894A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Charcot-Marie-Tooth disease1 trial

References

Drug Info

Quick Facts

Related News